Company

Vironexis Biotherapeutics

Biotechnology Research 11 employees

Employees: 11
Contacts: 4
Emails: 4
Phones: 1

vironexis.com LinkedIn Crunchbase

Vironexis Biotherapeutics Overview

Website: vironexis.com
Industry: Biotechnology Research
Employees: 11
Founded: 2021
Funding: 26.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

San Diego

About Vironexis Biotherapeutics

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

Vironexis Biotherapeutics Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 1; 25.0% coverage

Vironexis Biotherapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Allen Reha	Chief Development Officer, Vironexis	New York City Metropolitan Area, United States	Email Phone
Jacob Scott	Physician-scientist, Cleveland Clinic	Greater Cleveland, United States	Email
Tracy Lou	Director, Clinical Operations	San Francisco Bay Area, United States	Email
Debashree Das	Associate Director, Science	San Diego, California, United States	Email